This is the authors' abstract. We don't add key points for this paper.
In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin were assessed against 20 carbapenem-resistant clinical isolates with different mechanisms of carbapenem resistance. Bactericidal activity was achieved in 90% of all bacteria assayed using combinations of polymyxin B, doripenem, and rifampin against five each of the carbapenem-resistant Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Escherichia coli isolates studied. Combinations with these antibacterials may provide a strategy for treatment of patients infected with such organisms.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Urban et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: